Bracco Announces $230 Million Investment to Construct First U.S. Injectable Contrast Media Manufacturing Plant
Bracco has announced a significant financial commitment of $230 million dedicated to building a new manufacturing facility located in Sanford, North Carolina. According to the company, this upcoming plant will serve as its very first domestic production site in the United States specifically focused on creating injectable contrast media used in diagnostic imaging procedures.
Expanding Domestic Production Capabilities
Contrast agents are specialized substances administered to patients during various diagnostic imaging procedures, such as X-rays, computed tomography scans, and magnetic resonance imaging, to improve the visibility of internal structures, blood vessels, and tissues. By establishing a dedicated manufacturing plant within the United States, Bracco aims to bolster its regional supply chain infrastructure for these essential clinical materials.
Details of the Sanford Facility
The new manufacturing site in Sanford represents a major capital investment by the company to support healthcare providers and imaging centers across the country. Key aspects of the planned development include:
- A total financial investment reaching $230 million.
- Location situated in Sanford, North Carolina.
- Designation as the company’s inaugural U.S. manufacturing facility for injectable contrast media.
Company representatives noted that establishing local production capacity is expected to streamline distribution logistics for hospitals and diagnostic clinics relying on a steady supply of contrast agents to perform routine and advanced patient evaluations.
